Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Subcutaneous depot medroxyprogesterone acetate
Protara Therapeutics
Contraception
1 trial -
Subcutaneous glargine insulin
Lxo Ireland Designated Activity Company
Diabetes Mellitus
1 trial -
Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484
Indivior Pty Ltd
Opiate Dependence
1 trial -
Subutex 300 mg injektionsvätska, depotlösning, Subutex 100 mg injektionsvätska, depotlösning
Indivior Pty Ltd
Opioid Use Disorder
1 trial -
Sufentanil
The First People's Hospital of Lianyungang
Arteriovenous Malformation
1 trial -
Sugammadex hameln 100 mg/ml oplossing voor injectie, Naloxon HCl Accord 0,4 mg/ml, oplossing voor injectie / infusie in een voorgevulde spuit, ANEXATE 0,5 mg/5 ml, solution injectable (I.V.), REMIMAZOLAM , Sufentanil Viatris 5 microgram/ml oplossing voor injectie, Esmeron 10 mg/ml, oplossing voor injectie
Disc Medicine
General anesthesia
1 trial -
Sulfadoxine-pyrimethamine
United Therapeutics Europe Ltd
Malaria (Uncomplicated)
1 trial -
Sulfato de Magnesio Altan 150 mg/ml solución inyectable y para perfusión EFG, LIDOCAINE HYDROCHLORIDE, Dexdor 100 micrograms/ml concentrate for solution for infusion, KETOLAR 50 mg/ml solución inyectable.
The George Institute
Obesity
1 trial -
Surabgene Lomparvovec (ABBV-RGX-314), Lucentis 10 mg/ml solution for injection in pre-filled syringe, Surabgene Lomparvovec (ABBV-RGX-314)
AbbVie Deutschland GmbH & Co. KG
Neovascular age-related macular degeneration
1 trial -
Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide)
GT Biopharma
Glioblastoma
1 trial -
Suzetrigine
Vertex Pharmaceuticals (Australia) Pty.
Pain
6 trials -
Suzetrigine
Vertex Pharmaceuticals (Australia) Pty.
Acute Pain
2 trials -
Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg
AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
Synacthen (Tetracosactrin)
Cardiff Oncology
Healthy
1 trial -
T-jet® containing TevTropin®
Teva Pharma GmbH
Growth Hormone Deficiency
1 trial -
TACROLIMUS, SIROLIMUS, MYCOPHENOLATE MOFETIL, AZATHIOPRINE, PREDNISOLONE, EVEROLIMUS, MYCOPHENOLIC ACID, BELATACEPT, CICLOSPORIN
The George Institute
BK Polyomavirus DNAemia after kidney transplantation
1 trial -
TAGRISSO 80 mg film-coated tablets
Disc Medicine
EGFR mutated locally advanced or metastatic non-small cell lung cancer
1 trial -
TAGRISSO 80 mg film-coated tablets
Disc Medicine
EGFR mutated locally advanced or metastatic non-small cell lung cancer
1 trial -
TAGRISSO 80 mg film-coated tablets
Fondazione Telethon ETS
Patients with EGFR mutant NSCLC according to TP53 mutational status
1 trial -
TESTOGEL 50 mg gel transdérmico en sobres, Decapeptyl diario 0,1 mg polvo y disolvente para solución inyectable, Bemfola 300 IU/0.50 mL solution for injection in pre-filled pen, Astarté 0,25 mg/0,5 ml solución inyectable en jeringa precargada EFG
The George Institute
low ovarian reserve according to Bologna criteria and carriers of androgen receptor polymorphism
1 trial -
TICAGRELOR
Disc Medicine
Acute coronary syndrome
1 trial -
TILMANOCEPT, TILMANOCEPT, GALLIUM (68GA) CHLORIDE, TECHNETIUM (99MTC)
Disc Medicine
Oral cancer
1 trial -
TIMOFEROL 50 mg, comprimé enrobé, TIMOFEROL, gélule, FERRIC CARBOXYMALTOSE
Pari Pharma GmbH
Women who delivered by caesarean and have a moderate postpartum iron deficiency anaemia defined by 8.0 g/dL ≤ postoperative Hb level ≤ 10.0 g/dL within 72h after delivery and a ferritinemia ≤ 100 ng/mL OR transferrin saturation ≤ 20% (Measured after postoperative Hb level measurement)
1 trial -
TMT212, TMT212, Mekinist 0.5 mg film-coated tablets, Mekinist 2 mg film-coated tablets, DRB436, DRB436, DRB436, TMT212
Novartis Pharmaceuticals
Multiple indications
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources